NCT05295212View on ClinicalTrials.gov

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

July 1, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Atezolizumab

Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER